insulin glargine

GPTKB entity

Statements (55)
Predicate Object
gptkbp:instance_of gptkb:Company
gptkbp:bfsLayer 4
gptkbp:bfsParent gptkb:Basaglar
gptkb:Lantus
gptkbp:activities provides a steady level of insulin
gptkbp:appointed_by subcutaneous injection
gptkbp:approves gptkb:2000
gptkb:FDA
gptkbp:availability prescription only
gptkbp:brand gptkb:Basaglar
gptkb:Toujeo
gptkbp:class long-acting insulin
gptkbp:clinical_trial studied for cardiovascular outcomes
studied for efficacy in glycemic control
studied for long-term safety
gptkbp:contraindication hypersensitivity to insulin glargine
gptkbp:developed_by gptkb:Sanofi
gptkbp:duration up to 24 hours
gptkbp:education storage instructions
recognizing hypoglycemia symptoms
diet and exercise importance
importance of blood glucose monitoring
proper injection techniques
gptkbp:financial_performance up to 28 days at room temperature
gptkbp:formulation solution for injection
https://www.w3.org/2000/01/rdf-schema#label insulin glargine
gptkbp:indication gptkb:Type_1_diabetes
Type 2 diabetes
gptkbp:ingredients C267 H404 N72 O80 S6
gptkbp:interacts_with with beta-blockers
with corticosteroids
with other antidiabetic medications
with thiazolidinediones
gptkbp:is_available_on vial
pre-filled pen
gptkbp:is_used_for diabetes management
gptkbp:marketed_as gptkb:Lantus
gptkbp:pharmacokinetics slow absorption
insulin receptor agonist
gptkbp:population gptkb:Person
adults
gptkbp:premiered_on 1 to 2 hours
gptkbp:previous_name gptkb:insulin_glargine
gptkbp:price varies by region
gptkbp:provides_information_on EASD guidelines
ADA Standards of Medical Care
gptkbp:safety_features liver function assessment
monitoring for allergic reactions
monitoring for injection site reactions
regular Hb A1c testing
renal function assessment
gptkbp:side_effect weight gain
injection site reactions
hypoglycemia
gptkbp:storage refrigerated